Adaptimmune Therapeutics plc Total Current Liabilities

Adaptimmune Therapeutics plc (ADAPY) currently reports a total current liabilities of $52M as of June 2025. That compares with $82M in the prior-year period — down 37.2% year over year. Use the charts on this page to explore Adaptimmune Therapeutics plc's total current liabilities history and peer comparisons.

Adaptimmune Therapeutics plc's total current liabilities decreased from $82M to $52M — a 37.2% year-over-year decrease (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adaptimmune Therapeutics plc reported $52M in total current liabilities as of June 2025. That compares with $82M in the prior-year period — down 37.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $52M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Adaptimmune Therapeutics plc, and consider following ADAPY for alerts when major investors trade the stock.

Adaptimmune Therapeutics plc is classified in the Healthcare sector. On total current liabilities, it currently shows $52M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADAPY with unrelated industries.